Skip to main content

MelroseWakefield Hospital Is the First in New England To Offer New, Minimally Invasive, Robotic Treatment for Enlarged Prostates

November 11, 2021

MelroseWakefield Hospital is the first in New England to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. Half of all men ages 51 to 60 have BPH and the incidence increases every decade of life.

If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones and incontinence.

Many current BPH surgical treatments often force men to trade off between symptom relief and side effects, limiting patients to choose between either a high degree of symptom relief with high rates of irreversible complications (such as incontinence, erectile dysfunction or ejaculatory dysfunction) or low degree of symptom relief with low rates of irreversible complications.

Aquablation therapy is a different type of treatment for BPH. It’s an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide best-in-class and long-lasting symptom relief with low rates of irreversible complications, regardless of prostate size or shape.

“We are proud to be among the first in New England to offer a solution for men with BPH that provides BPH relief without compromise,” said urologist Richard Caesar, MD. “Aquablation therapy is the next step to furthering our commitment to robotic surgery and men’s health”

Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection or the treatment of LUTS due to BPH. It combines real-time, multi-dimensional imaging, automated robotic technology and heat-free waterjet ablation technology for targeted, controlled and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size or surgeon experience.

Aquablation therapy has proven results. In clinical studies, Aquablation therapy has shown to provide both best-in-class and durable symptom relief with low rates of irreversible complications.

A study within the Journal of Sexual Medicine, which surveyed 300 men living with BPH, revealed 92% of respondents expressed an interest in learning more about Aquablation therapy. This data demonstrates the need within the patient population to find relief without the trade-off between symptoms and relief side effects.

The Healthy Podcast
Prostate Health With Dr. Richard Caesar
Half of all men ages 51 to 60 have benign prostatic hyperplasia (BPH) and the incidence increases every decade of life.
Articles
What You Need To Know about Prostate Cancer
Prostate cancer is the most common cancer in American men and also the most common non-skin cancer among all Americans.
Press Releases
Novel Drug for Treatment of Upper Tract Urothelial Cancer
Tufts Medical Center announced today that it has become the first center in New England to use the drug Jelmyto (UroGen Pharma, Inc.) for treatment of upper tract urothelial cancer (UTUC), a malignancy found in the kidney lining or the ureter, the thin tube connecting the bladder to the kidneys.

Be among the first to know

Enjoy the latest health updates from Tufts Medicine by signing up for our e-newsletter today.

Jump back to top